A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Paclitaxel Albumin Nanoparticle for Injectable Suspension
Sponsor: Veeda Oncology
Collaborators: Celgene Corporation